China’s SFDA Rapid Response To Biopharmaceutical-Triggered Deaths Seen As Progress By Industry Observers

BEIJING - In a case that closely parallels FDA's investigation of the drug heparin, China's State FDA is now examining a biopharmaceutical that triggered severe adverse reactions in seven Chinese patients, six of whom have died